LEXINGTON, Mass., June 4 /PRNewswire/ -- Synta Pharmaceuticals Corp., an
emerging pharmaceutical company, today announced the appointment of John A.
McCarthy, Jr. as Senior Vice President Corporate Development and Chief
Financial Officer, and Jeremy G. Chadwick, Ph.D. as Vice President, Program
"An essential part of growing our business and effectively executing our
multi-product development program is attracting the type of highly-
experienced, talented, and high energy individuals we have on our current
management team and in the new additions announced today," stated Safi
Bahcall, Ph.D., President and Chief Executive Officer. "John brings to Synta
an outstanding history as a seasoned financial executive with broad-based
healthcare experience, as well as the proven leadership skills needed to help
manage a rapidly growing business. John's experience in successfully
structuring and negotiating complex business partnerships will also add
strength to our business development initiatives. I expect John to be a great
complementary addition to the senior management team at Synta."
John McCarthy joins Synta from Exact Sciences Corporation where he most
recently served as Executive Vice President and Chief Financial Officer. Mr.
McCarthy joined Exact Sciences in 2000 as a privately-held company and shortly
thereafter led its successful initial public offering and subsequent public
financing. Additionally, Mr. McCarthy was instrumental in developing the
strategic corporate partnerships and operational infrastructure necessary for
the company's national launch of its first commercial product in 2003. Prior
to Exact Sciences, Mr. McCarthy's healthcare experience included serving as
President of InfoMedtrics Corporation (privately-held), President of the
Managed Care Division of Concentra Managed Care, Inc. (publicly-traded), and
SVP and CFO of MedChem Products, Inc. (publicly-traded). Additionally, Mr.
McCarthy's prior experience included serving as an investment banking
associate with Morgan Stanley. Mr. McCarthy is a graduate of Lehigh
University and Harvard Business School.
"Synta has provided me with a truly unique opportunity to join a company
with both the breadth and depth in its pipeline to address some of the largest
market opportunities in the industry," said Mr. McCarthy. "Additionally, the
company's strong balance sheet and dedicated investor base provide it with
considerable flexibility to focus on long-term shareholder value creation. I
am very excited to be joining Synta at this important stage of its development
and look forward to working with the exceptional team that has been built to
Jeremy Chadwick, Ph.D. joins Synta as Vice President, Program Management
from Vertex Pharmaceuticals Inc. where he most recently served as Vice
President, Development Operations. During his tenure at Vertex, Dr.
Chadwick's responsibilities were multi-dimensional and included outsourcing,
planning, new systems and technologies, portfolio management, drug safety,
medical writing and clinical pharmacology. Dr. Chadwick's responsibilities
also included chairing Vertex's Development Advisory Board. Prior to joining
Vertex, Dr. Chadwick held various positions including Vice President, US
Biostatistics and Data Management at Parexel International; Senior Manager,
Medical Data Sciences Division, Glaxo Group Research; and Chief Operating
Officer at Foliage Software Systems, a privately-held high-end software
development company. Dr. Chadwick obtained both his Masters and Ph.D. in
Statistics from the University of London, UK.
"Jeremy's 15-year drug development and program management experience
working on multiple NDAs in the biopharmaceutical industry will be an
important contribution to the success of our growing development portfolio,"
stated Dr. Matthew Sherman, Senior Vice President and Chief Medical Officer.
Dr. Chadwick added, "I am extremely excited to be joining Synta at such an
important point in time. With a rich pipeline, outstanding people and strong
financial backing we have an opportunity to aggressively move several
compounds though the clinic. I look forward to contributing to the company's
success with the entire Synta team."
Synta Pharmaceuticals is an emerging pharmaceutical company focused on
discovering, developing, and commercializing breakthrough products for severe
medical conditions. Synta has a diverse pipeline of small-molecule
therapeutics for the treatment of cancer and immune disorders, with its two
most advanced products in Phase II clinical development. Synta developed as a
buyout of the U.S. subsidiary of a large Japanese pharmaceutical company. As
a result, Synta has an experienced and successful drug discovery team that has
worked together for over ten years. All clinical candidates were developed by
this team using Synta's chemistry-driven drug discovery platform. Synta fully
owns all rights for all of its products. For more information, please see
Synta Pharmaceuticals Corp. Euro RSCG Life NRP
Safi Bahcall, Ph.D. Robert Stanislaro
President & Chief Executive Officer Senior Account Executive
SOURCE Synta Pharmaceuticals Corp.